瑞典转移性乳腺癌患者的总生存率：一项全国性研究。

Overall survival of patients with metastatic breast cancer in Sweden: a nationwide study.

机构信息

Department of Oncology, Faculty of Medicine and Health, Örebro University Hospital, Örebro, 701 05, Sweden.

Nordic Market Access AB, Stockholm, 113 59, Sweden.

出版信息

Br J Cancer. 2022 Sep;127(4):720-725. doi: 10.1038/s41416-022-01845-z. Epub 2022 May 21.

DOI:10.1038/s41416-022-01845-z

PMID:35597870

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9381497/

Abstract

BACKGROUND

Breast cancer is the most common cancer among women in Sweden. Whereas survival for the overall breast cancer population is well-documented, survival of patients with metastatic breast cancer (MBC) is harder to quantify due to the lack of reliable data on disease recurrence in national cancer registers.

METHODS

This study used machine learning to classify the total MBC population in Sweden diagnosed between 2009 and 2016 using national registers, with the aim to estimate overall survival (OS).

RESULTS

The total population consisted of 13,832 patients-2528 (18.3%) had de novo MBC whereas 11,304 (81.7%) were classed as having a recurrent MBC. Median OS for patients with MBC was found to be 29.8 months 95% confidence interval (CI) [28.9, 30.6]. Hormone-receptor (HR)-positive MBC had a median OS of 37.0 months 95% CI [35.9, 38.3] compared to 9.9 months 95% CI [9.1, 11.0] for patients with HR-negative MBC.

CONCLUSION

This study covered the entire MBC population in Sweden during the study time and may serve as a baseline for assessing the effect of new treatment strategies in MBC introduced after the study period.

摘要

背景

乳腺癌是瑞典女性中最常见的癌症。尽管整体乳腺癌患者的生存率已有详细记录，但转移性乳腺癌（MBC）患者的生存率由于国家癌症登记处缺乏关于疾病复发的可靠数据而难以量化。

方法

本研究使用机器学习对 2009 年至 2016 年间在国家登记处诊断的瑞典总 MBC 人群进行分类，目的是估计总体生存率（OS）。

结果

总人群由 13832 名患者组成-2528 名（18.3%）为初发 MBC，11304 名（81.7%）为复发性 MBC。MBC 患者的中位 OS 为 29.8 个月 95%置信区间（CI）[28.9, 30.6]。激素受体（HR）阳性 MBC 的中位 OS 为 37.0 个月 95%CI[35.9, 38.3]，而 HR 阴性 MBC 的中位 OS 为 9.9 个月 95%CI[9.1, 11.0]。